NxStage Medical, Inc. (NXTM) Expected to Post Earnings of -$0.03 Per Share
Wall Street brokerages predict that NxStage Medical, Inc. (NASDAQ:NXTM) will announce earnings of ($0.03) per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for NxStage Medical’s earnings, with estimates ranging from ($0.03) to ($0.02). NxStage Medical posted earnings of ($0.02) per share in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The business is scheduled to issue its next quarterly earnings report before the market opens on Tuesday, May 9th.
On average, analysts expect that NxStage Medical will report full-year earnings of ($0.01) per share for the current financial year, with EPS estimates ranging from ($0.10) to $0.02. For the next financial year, analysts anticipate that the business will post earnings of $0.14 per share, with EPS estimates ranging from $0.02 to $0.20. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Tuesday, February 28th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.02). The business earned $93.01 million during the quarter, compared to the consensus estimate of $91.82 million. NxStage Medical had a negative net margin of 1.61% and a negative return on equity of 2.97%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) EPS.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/20/nxstage-medical-inc-nxtm-expected-to-post-earnings-of-0-03-per-share.html
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research lowered NxStage Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 5th. Northland Securities reaffirmed a “buy” rating and set a $35.00 target price on shares of NxStage Medical in a research report on Monday, April 3rd. Jefferies Group LLC boosted their target price on NxStage Medical to $38.00 and gave the stock a “buy” rating in a research report on Monday, February 6th. Finally, Canaccord Genuity set a $31.00 target price on NxStage Medical and gave the stock a “buy” rating in a research report on Monday, January 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $29.67.
NxStage Medical (NASDAQ:NXTM) opened at 27.37 on Thursday. The stock has a 50 day moving average of $27.17 and a 200-day moving average of $26.19. The stock’s market cap is $1.78 billion. NxStage Medical has a one year low of $15.30 and a one year high of $29.99.
In related news, CEO Jeffrey H. Burbank sold 7,500 shares of the company’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $29.01, for a total transaction of $217,575.00. Following the transaction, the chief executive officer now directly owns 943,749 shares of the company’s stock, valued at $27,378,158.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction on Thursday, April 13th. The shares were sold at an average price of $26.10, for a total value of $26,100.00. Following the transaction, the president now directly owns 78,903 shares in the company, valued at $2,059,368.30. The disclosure for this sale can be found here. Insiders have sold 251,892 shares of company stock worth $6,817,161 over the last three months. 4.70% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC raised its position in NxStage Medical by 40.6% in the third quarter. Acrospire Investment Management LLC now owns 6,578 shares of the medical device company’s stock valued at $164,000 after buying an additional 1,900 shares during the last quarter. Fortaleza Asset Management Inc. raised its position in NxStage Medical by 2.5% in the fourth quarter. Fortaleza Asset Management Inc. now owns 8,055 shares of the medical device company’s stock valued at $211,000 after buying an additional 195 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in NxStage Medical by 56.8% in the third quarter. BNP Paribas Arbitrage SA now owns 8,700 shares of the medical device company’s stock valued at $217,000 after buying an additional 3,152 shares during the last quarter. Tudor Investment Corp Et Al acquired a new position in NxStage Medical during the fourth quarter valued at $233,000. Finally, Airain ltd acquired a new position in NxStage Medical during the third quarter valued at $304,000. 97.26% of the stock is currently owned by hedge funds and other institutional investors.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.